دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Cover Image, Volume 24, Issue 12
Takashi Kadowaki MD, Hiroshi Maegawa MD, Hirotaka Watada MD, Daisuke Yabe MD, Koichi Node MD, Toyoaki Murohara MD, Jun Wada MD,Â
doi : 10.1111/dom.14114
Volume 24, Issue 12
Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan
Takashi Kadowaki MD, Hiroshi Maegawa MD, Hirotaka Watada MD, Daisuke Yabe MD, Koichi Node MD, Toyoaki Murohara MD, Jun Wada MD,Â
doi : 10.1111/dom.14829
Insights from epidemiological, clinical and basic research are illuminating the interplay between metabolic disorders, cardiovascular disease (CVD) and kidney dysfunction, termed cardio-renal-metabolic (CRM) disease.
Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment
Vanita R. Aroda MD, Robert H. Eckel MD,Â
doi : 10.1111/dom.14830
It is well known that the multiple factors contributing to the pathogenesis of type 2 diabetes (T2D) confer an increased risk of developing cardiovascular disease (CVD).
Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents
Korey K. Hood PhD, Natasha Garcia-Willingham PhD, Sarah Hanes BS, Molly L. Tanenbaum PhD, Julia Ware MD, Charlotte K. Boughton PhD, Janet M. Allen RN, Malgorzata E. Wilinska PhD, Martin Tauschmann MD, Louise Denvir MD, Ajay Thankamony MD, Fiona Campbell MD, R. Paul Wadwa MD, Bruce A. Buckingham MD, Nikki Davis MD, Linda A. DiMeglio MD, Nelly Mauras MD, Rachel E. J. Besser PhD, Atrayee Ghatak MD, Stuart A. Weinzimer MD, D. Steven Fox MD, Lauren Kanapka MSc, Craig Kollman PhD, Judy Sibayan MPH, Roy W. Beck PhD, Roman Hovorka PhD, on behalf of the DAN05 Consortium ,Â
doi : 10.1111/dom.14815
To examine changes in the lived experience of type 1 diabetes after use of hybrid closed loop (CL), including the CamAPS FX CL system.
Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial
Elena Succurro MD, Patrizia Vizza PhD, Annalisa Papa MD, Sofia Miceli MD, Francesco Cicone MD, Teresa Vanessa Fiorentino MD, Angela Sciacqua MD, Francesco Andreozzi MD, Pierangelo Veltri PhD, Giuseppe Lucio Cascini MD, Giorgio Sesti MD,Â
doi : 10.1111/dom.14816
To determine whether treatment with empagliflozin was able to affect the myocardial glucose metabolic rate, as assessed by cardiac dynamic 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) combined with euglycaemic-hyperinsulinaemic clamp compared with glimepiride in patients with type 2 diabetes.
TOTUM-63, a plant-based polyphenol-rich extract, improves glycaemic control in subjects with prediabetes or early stage newly-diagnosed type 2 diabetes in a randomized, double-blind, placebo-controlled trial
Pascal Sirvent PhD, Vivien Chavanelle PhD, Yolanda F. Otero PhD, Maxime Bargetto MSc, Florian Le Joubioux PhD, Nathalie Boisseau PhD, Thierry Maugard PhD, Murielle Cazaubiel MSc, Bruno Pereira PhD, Bruno Guigas PhD, Samy Hadjadj MD, Sebastien L. Peltier PhD, André Marette PhD, Jean-Marie Bard PhD,Â
doi : 10.1111/dom.14817
The plant-based polyphenol-rich extract TOTUM-63 improves glucose homeostasis in various preclinical models of obesity and type 2 diabetes (T2D). A pilot exploratory study showed that TOTUM-63 has good safety and tolerability profiles, and beneficial effects on postprandial glucose control in healthy individuals with overweight.
Revisiting ‘intensive’ blood glucose control: A causal directed acyclic graph-guided systematic review of randomized controlled trials
Chi-Jung Huang PhD, Wei-Ting Wang MD, Shih-Hsien Sung MD, Chen-Huan Chen MD, Gregory Y. H. Lip MD, Hao-Min Cheng MD, Chern-En Chiang MD,Â
doi : 10.1111/dom.14819
To clarify the importance of HbA1c reduction and antidiabetic drug use in preventing major adverse cardiovascular events (MACE) for patients with type 2 diabetes (T2D).
Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists
Neil Tanday PhD, Ryan A. Lafferty PhD, Peter R. Flatt PhD, Nigel Irwin PhD,Â
doi : 10.1111/dom.14821
To examine whether sequential administration of (d-Arg35)-sea lamprey peptide tyrosine tyrosine (1–36) (SL-PYY) and the glucagon-like peptide-1 (GLP-1) mimetic, liraglutide, has beneficial effects in diabetes.
Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial
William H. Polonsky PhD, Francesco Giorgino MD, Julio Rosenstock MD, Katherine Whitmire NP-c, BC-ADM, Elisheva Lew MS, Mathieu Coudert MSc, Agustina Alvarez MD, Charlie Nicholls PhD, Rory J. McCrimmon MD,Â
doi : 10.1111/dom.14822
To assess patient-reported outcomes (PROs) in the SoliMix trial, which compared the efficacy and safety of iGlarLixi versus BIAsp 30 in people with type 2 diabetes (T2D).
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months
Bruno Guerci MD, Francesco Giorgino MD, Hélène Sapin MSc, Kristina Boye PhD, Jérémie Lebrec PhD, Marco Orsini Federici PhD, Elke Heitmann PhD, Anne Dib MD, Martin Füchtenbusch MD, Luis-Emilio GarcÃa-Pérez MD,Â
doi : 10.1111/dom.14823
The primary objective of the TROPHIES observational study is to estimate the duration of treatment on dulaglutide or liraglutide without a significant treatment change by 24 months in patients with type 2 diabetes (T2D) initiating their first injectable treatment with these glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This manuscript presents 12-month interim data.
Evaluation of continuous glucose monitoring-derived person-specific HbA1c in the presence and absence of complications in type 1 diabetes
Yongjin Xu PhD, Philippe Oriot MD, Timothy C. Dunn PhD, Michel P. Hermans MD, Yashesvini Ram PhD, Alan Cheng PhD, Ramzi A. Ajjan PhD,Â
doi : 10.1111/dom.14824
To evaluate the accuracy of a novel kinetic model at predicting HbA1c in a real-world setting and to understand and explore the role of diabetes complications in altering the glucose–HbA1c relationship and the mechanisms involved.
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
Rory J. McCrimmon MD, Philip Home DM, Alice Cheng MD, Francesco Giorgino MD, Vivian Fonseca MD, Elisabeth Souhami MD, Agustina Alvarez MD, Pascaline Picard MSc, Julio Rosenstock MD,Â
doi : 10.1111/dom.14825
To explore details of the incidence and rates of daytime and nocturnal hypoglycaemia, levels of hypoglycaemia, and relationship to glycated haemoglobin (HbA1c), when comparing iGlarLixi versus premixed biphasic insulin aspart 30 (BIAsp 30) in the SoliMix randomized controlled trial.
Separate and combined effect of visit-to-visit glycaemic variability and mean fasting blood glucose level on all-cause mortality in patients with type 2 diabetes: A population-based cohort study
Yahang Liu, Huilin Xu, Jun Li, Yating Yang, Jie Zhang, Xiaoqin Liu, Jiong Li, Yongfu Yu, Guoyou Qin,Â
doi : 10.1111/dom.14826
To assess the independent and combined impacts of visit-to-visit fasting blood glucose variability (VVV-FBG) and mean fasting blood glucose level (M-FBG) on all-cause mortality.
Preclinical pharmacology of RA15127343: In vitro and in vivo activity of a novel ultralong-acting basal insulin
Ulrich Werner PhD, Maximilian Bielohuby PhD, Marcus Korn PhD, Jens Riedel PhD, Martin Will PhD, MarÃa Méndez PhD,Â
doi : 10.1111/dom.14827
To report the in vitro and in vivo preclinical pharmacokinetic (PK) and pharmacodynamic (PD) properties of RA15127343, a novel ultralong-acting insulin analogue targeting once-weekly administration, in female Göttingen minipigs.
Increased prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes and hypertension: The SWEET international database
Andriani Vazeou, Sascha R. Tittel, Olga Kordonouri, Niels H. Birkebaek, Violeta Iotova, Barbara Piccini, Sebastian Seget, Pravesh Kumar Guness, David M. Maahs, George S. Stergiou,Â
doi : 10.1111/dom.14834
To investigate the prevalence of modifiable cardiovascular risk factors (CVRFs), including dyslipidaemia, obesity and high glycated haemoglobin (HbA1c) concentration, in patients with type 1 diabetes (T1D), and to evaluate their association with blood pressure (BP) categories.
Very low carbohydrate (ketogenic) diets in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials
Amber Parry-Strong PhD, Morag Wright-McNaughton BSc, Mark Weatherall BA, Rosemary M. Hall PhD, Kirsten J. Coppell MBChB, Christine Barthow PhD, Jeremy D. Krebs MD,Â
doi : 10.1111/dom.14837
Very low carbohydrate/ketogenic diets (VLC/KDs) are popular but their role in managing pre-diabetes and type 2 diabetes (T2D) is uncertain. This study uses a systematic review and meta-analysis of randomized controlled trials to estimate the effect of these diets in this population.
Effect of renin-angiotensin system antihypertensive medication use on cognitive function in diabetes mellitus with obesity or overweight: An ancillary study to the Action for Health in Diabetes (Look AHEAD) trial
Whitney Wharton PhD, Andrea Anderson MS, Kathleen M. Hayden PhD, Owen T Carmichael PhD, Jeanne M Clark MD, José A. Luchsinger MD, Mark Espeland PhD, Sevil Yasar MD,Â
doi : 10.1111/dom.14838
To determine whether antihypertensive medication (AHM) acting through the renin angiotensin system (RAS-AHM), compared with other AHM, can mitigate effects on cognitive function and risk for impairment in a population with type 2 diabetes mellitus (T2DM).
Hepatic steatosis and advanced fibrosis are independent predictors of mortality in acute myocardial infarction without standard modifiable risk factors
Nicholas WS Chew, Gemma A Figtree, Gwyneth Kong, Steve Vernon, Mark Muthiah, Cheng Han Ng, Mark Y Chan, Poay H Loh,Â
doi : 10.1111/dom.14820
Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program
Julio C. Nunes MD, Jie Yu MD, Clare Arnott MD, Meg J. Jardine PhD, Vlado Perkovic MD, Kenneth W. Mahaffey MD,Â
doi : 10.1111/dom.14832
Are angiotensin-converting enzyme inhibitors/angiotensin receptor blockers associated with reduced severe acute respiratory syndrome coronavirus 2 infections and improved outcomes, and does race matter?
John Armato MD, Ralph A. DeFronzo MD, Shih-Ting Chiu PhD, Deanna Rider, Ronald Ruby MD,Â
doi : 10.1111/dom.14835
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin
Yasuhiro Matsubayashi MD, Alkihiro Yoshida PhD, Hideki Suganami PhD, Momoko Oe MS, Takaaki Sato MD, Yuta Yaguchi MD, Kazuya Fujihara MD, Takaho Yamada MD, Shiro Tanaka PhD, Kohei Kaku MD, Hirohito Sone MD,Â
doi : 10.1111/dom.14836
A comparison of the effectiveness and safety of insulin glargine 300 U/ml versus 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: A retrospective, observational, short-term study
Ivana Rabbone MD, PhD, Erica Pozzi MD, Silvia Savastio MD, Galimberti Luca MD, Morotti Elisa MD, Frontino Giulio MD, Geremia B Bolli MD, Riccardo Bonfanti MD,Â
doi : 10.1111/dom.14839
Repetitive transcranial magnetic stimulation: A potential therapeutic option for obesity in a patient with Prader-Willi syndrome
Anna Ferrulli MD, PhD, Daniele Cannavaro MD, Concetta Macrì RN, Livio Luzi MD,Â
doi : 10.1111/dom.14833
